Alterations in the gut microbiome and metabolism with coronary artery disease severity

Abstract

Background Coronary artery disease (CAD) is associated with gut microbiota alterations in different populations. Gut microbe-derived metabolites have been proposed as markers of major adverse cardiac events. However, the relationship between the gut microbiome and the different stages of CAD pathophysiology remains to be established by a systematic study. Results Based on multi-omic analyses (sequencing of the V3-V4 regions of the 16S rRNA gene and metabolomics) of 161 CAD patients and 40 healthy controls, we found that the composition of both the gut microbiota and metabolites changed significantly with CAD severity. We identified 29 metabolite modules that were separately classified as being positively or negatively correlated with CAD phenotypes, and the bacterial co-abundance group (CAG) with characteristic changes at different stages of CAD was represented by Roseburia , Klebsiella , Clostridium IV and Ruminococcaceae . The result revealed that certain bacteria might affect atherosclerosis by modulating the metabolic pathways of the host, such as taurine, sphingolipid and ceramide, and benzene metabolism. Moreover, a disease classifier based on differential levels of microbes and metabolites was constructed to discriminate cases from controls and was even able to distinguish stable coronary artery disease from acute coronary syndrome accurately. Conclusion Overall, the composition and functions of the gut microbial community differed from healthy controls to diverse coronary artery disease subtypes. Our study identified the relationships between the features of the gut microbiota and circulating metabolites, providing a new direction for future studies aiming to understand the host–gut microbiota interplay in atherosclerotic pathogenesis. Electronic supplementary material The online version of this article (10.1186/s40168-019-0683-9) contains supplementary material, which is available to authorized users.

A Metabolic Insight Into the Neuroprotective Effect of Jin-Mai-Tong (JMT) Decoction on Diabetic Rats With Peripheral Neuropathy Using Untargeted Metabolomics Strategy

“…As described in our recent study (Liu et al, 2019), metabolites were identified according to their exact molecular weight and the MS/MS fragmentation pattern by comparison with those in the online HMDB database 3 (Wishart et al, 2018), KEGG database 4 (Kanehisa and Goto, 2000), and METLIN (Sud et al, 2007). The mass error was 10 ppm for MS 1 and 15 ppm for MS 2 .…”

Microbial community with predictive power can be a new non-invasive substitute for clinical and pathological identification of diabetic nephropathy

“…Further study is needed to explore whether these bacteria are useful for prevention of DKD. Such increase of opportunistic pathogens with commensurate decrease of SCFA-producing bacteria had been reported to be involved in the development of vascular or immune diseases, such as diabetes [16], atherosclerosis disease [11] and autoimmune hepatitis [32]. Thus, it was possible that expansion of harmful bacteria might only be a common feature possessed by varieties of disease, instead of disease-speci c, which just increased the host's susceptibility to disease.…”

“…The microorganic community varies substantially between different health or disease conditions. It is generally believed that gut microbiota is associated with degrading indigestible carbohydrates [7], promoting host immune tolerance [8] and even facilitating the development certain diseases [9][10][11]. Accordingly, a large number of studies have indicated its potential medical ability in area of early diagnosis, prognostic prediction, treatment strategy and so on.…”

Correlation Network Analyses Based on Metagenomics and Multi-type Metabolomic Data Identified Biomarkers of Coronary Artery Disease

“…Recent studies have shown an association between the gut microbiome and cardiovascular diseases [6].…”

“…For example, Li et al performed comprehensive metagenomic and metabolomic analyses, described a novel causal role of aberrant gut microbiota in hypertension pathogenesis and also veri ed the results in mouse models [14]. Liu et al identi ed 29 metabolite modules that were correlated with CAD phenotypes and constructed a classi er that could discriminate cases from controls [6]. Zhou et al provided the rst evidence that cardiovascular outcomes following myocardial infarction (MI) are driven by the intestinal microbiota [15].…”